Cost-Effectiveness Analysis (CEA) of Linezolid Versus Vancomycin in the Treatment of Nosocomial Pneumonia Caused by Methicillin-Resistant Staphylococcus Aureus (MRSA-NP) Based on a Phase IV Clinical Trial- Results from Four Major Cities in ...
Nov 1, 2013, 00:00
10.1016/j.jval.2013.08.209
https://www.valueinhealthjournal.com/article/S1098-3015(13)02114-1/fulltext
Title :
Cost-Effectiveness Analysis (CEA) of Linezolid Versus Vancomycin in the Treatment of Nosocomial Pneumonia Caused by Methicillin-Resistant Staphylococcus Aureus (MRSA-NP) Based on a Phase IV Clinical Trial- Results from Four Major Cities in ...
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)02114-1&doi=10.1016/j.jval.2013.08.209
First page :
A358
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
196